Tag: Implanet
Implanet entrusts its Listing Sponsor contract to the company Atout Capital – 01/03/2024 at 6:13 p.m.
(AOF) – Implanet, a medical technology company specializing in implants intended for orthopedic surgery and in the distribution of technological medical equipment, announces that it has entrusted its Listing Sponsor…
IMPLANET obtains approval from its shareholders for its capital increase project – 11/16/2023 at 7:00 p.m.
• Adoption of the resolutions at the Extraordinary General Meeting held today relating to the capital increase to take place in January 2024 Bordeaux, Boston, November 16, 2023 – 7:00…
Implanet: turnover down 17% in the 3rd quarter of 2023, tensions on cash flow – 10/17/2023 at 6:23 p.m.
(AOF) – Implanet announces a turnover of 1.53 million euros in the third quarter, down 17% year-on-year. The medical technology company specializing in implants intended for orthopedic surgery and in…
Implanet: turnover down 17% in the 3rd quarter of 2023, tensions on cash flow
(AOF) – Implanet announces a turnover of 1.53 million euros in the third quarter, down 17% year-on-year. The medical technology company specializing in implants intended for orthopedic surgery and in…
Implanet: the stock soars, fundraising reassures – 09/28/2023 at 12:34
(CercleFinance.com) – Implanet shares soar this Thursday on the Paris Stock Exchange, following the announcement by the orthopedic surgery specialist of a fundraising project which seems to reassure the market.…
IMPLANET announces the postponement of the publication of its 2023 half-year results – 09/19/2023 at 8:00 p.m.
Bordeaux, Boston, September 19, 2023 – 8:00 p.m. CEST: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), medical technology company specializing in implants intended for orthopedic surgery and in the…
IMPLANET publishes revenue of €4.3 million for the first half of 2023 – 2023-07-11 at 18:00
o Revenue of €2.1m in Q2 2023, stable compared to Q2 2022o Continued momentum in sales of the new Medical Equipment activity o First results of the technological alliance concluded…
IMPLANET announces the launch in Europe of the MIS range, a minimally invasive pedicle screw positioning system – 06/21/2023 at 18:00
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected] o First innovation resulting from…
IMPLANET obtains approval of the SqualeTM range of anterior cervical cages by the FDA in the United States – 04/11/2023 at 07:30
Bordeaux, Boston, April 11, 2023 – 7:30 a.m. CEST: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and in the…
IMPLANET will hold its Annual General Meeting on May 3, 2023 – 03/29/2023 at 6:00 p.m.
Bordeaux, Boston, March 29, 2023 – 6:00 p.m. CEST: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and in the…
IMPLANET announces its 2022 annual results – 2023-03-07 18:00
o Improvement of gross margin by +33%, to €5m o 15% reduction in operational loss o Improved net income from continuing operations by 23% o Reinforcement of Sanyou Medical in…
Implanet: improvement in gross margin in 2022
By Olivier Cheilan Published on 03/07/2023 at 6:38 p.m. (Boursier.com) — The gross margin of…